Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas A T
Am J Obstet Gynecol. 1985 Aug 15;152(8):1034-8. doi: 10.1016/0002-9378(85)90554-x.
Ten women with 12 uterine leiomyomas ranging from 7.5 to 420 cc (mean, 112.6 +/- 39.4) were treated with subcutaneous injections of the luteinizing hormone-releasing hormone agonist buserelin, 200 micrograms three times daily for 1 week and then 500 micrograms daily for the rest of the 6-month treatment period. Following initial stimulation the pituitary ovarian axis was suppressed after 3 weeks of treatment with mean serum estradiol ranging between 17 and 36 pg/ml. Seven uterine leiomyomas had a marked regression in size following treatment with luteinizing hormone-releasing hormone agonist; two were undetectable and the volume of the other five diminished by an average of 80%. One tumor did not respond to treatment, two regressed by 25%, and two, following an initial reduction of 65% and 50%, reenlarged during the last 2 months of treatment to 75% and 100% respectively of their initial volume. Luteinizing hormone-releasing hormone agonist is the first medication demonstrated effective in reducing the size of uterine myomas.
10名患有12个子宫平滑肌瘤的女性，肌瘤大小从7.5至420立方厘米不等（平均为112.6±39.4），接受了皮下注射促黄体生成素释放激素激动剂布舍瑞林的治疗，每天3次，每次200微克，持续1周，然后在为期6个月的治疗期剩余时间里每天注射500微克。在最初的刺激后，治疗3周后垂体-卵巢轴被抑制，血清雌二醇平均水平在17至36皮克/毫升之间。7个子宫平滑肌瘤在接受促黄体生成素释放激素激动剂治疗后大小显著缩小；2个无法检测到，另外5个的体积平均减少了80%。1个肿瘤对治疗无反应，2个缩小了25%，还有2个在最初分别缩小了65%和50%后，在治疗的最后2个月又重新增大至初始体积的75%和100%。促黄体生成素释放激素激动剂是第一种被证明对减小子宫肌瘤大小有效的药物。
